Dendrimer-N-acetyl cysteine (D-NAC) conjugate has shown significant promise in multiple preclinical models of brain injury and is undergoing clinical translation. D-NAC is a generation-4 hydroxylpolyamidoamine dendrimer conjugate where N-acetyl cysteine (NAC) is covalently bound through disulfide linkages on the surface of the dendrimer. It has shown remarkable potential to selectively target and deliver NAC to activated microglia and astrocytes at the site of brain injury in several animal models, producing remarkable improvements in neurological outcomes at a fraction of the free drug dose. Here we present a highly efficient, scalable, greener, well-defined route to the synthesis of D-NAC, and validate the structure, stability and activity to define the benchmarks for this compound. This newly developed synthetic route has significantly reduced the synthesis time from three weeks to one week, uses industry-friendly solvents/reagents, and involves simple purification procedures, potentially enabling efficient scale up. for enhanced delivery across the BBB. These approaches can be valuable but may not be feasible in clinical settings when multiple therapeutic doses are required. In addition, the need to further deliver the drugs to cells far away from the BBB is a challenge. Neuroinflammation, mediated by activated microglia and astrocytes, has been shown to play a key role in various neurological diseases making it a potential therapeutic target. 6-9 Neuroinflammation causes transient disruption
| I N TR ODU C TI ON
Drug development for central nervous system (CNS) disorders is highly challenging as compared to other disease targets. The critical obstacle in this endeavor is the delivery of therapeutics across the blood brain barrier (BBB) which controls the passage of molecules from circulatory system into the brain. 1, 2 Various invasive and non-invasive techniques are currently being explored to get appropriate exposure of therapeutics into the brain. 1, [3] [4] [5] Invasive strategies involve the temporary disruption of the BBB or direct injections into CNS tissues, while noninvasive approaches primarily utilize endogenous cellular mechanisms for enhanced delivery across the BBB. These approaches can be valuable but may not be feasible in clinical settings when multiple therapeutic doses are required. In addition, the need to further deliver the drugs to cells far away from the BBB is a challenge. Neuroinflammation, mediated by activated microglia and astrocytes, has been shown to play a key role in various neurological diseases making it a potential therapeutic target. [6] [7] [8] [9] Neuroinflammation causes transient disruption of the BBB through loosening of the tight junctions of the epithelial layer, resulting in increased permeability under certain pathological conditions. 10 This impaired BBB in neuroinflammatory disorders presents an excellent opportunity to transport therapeutic molecules or drug-loaded nanoparticles into the brain via intravenous administration.
Recently, the field of drug delivery has been revolutionized with a plethora of innovative nanotechnology-based products which can effectively diffuse through the biological barricades within the body and deliver payloads of drugs, DNA, proteins or peptides to injured or diseased cells and tissues. [11] [12] [13] [14] [15] [16] Despite the significant growth in the field of nanotechnology, nanoparticles face challenges during clinical translation. Major challenges include reproducible scale-up of the synthesis, and definition of the benchmarks of the final product and the stability. 17 Maintaining batch-to-batch consistency in physico-chemical, pharmacological and biological properties is critical for enabling translation. The utility of a nano-therapeutic in the clinic greatly depends upon its safety profile which is governed by its components, size, charge, and other physiochemical properties. 18 The risk of failure can be minimized beforehand by carefully selecting rationally designed
components that have already been tested and approved and can be incorporated together for the preparation of the particle.
Dendrimers are structurally "monodisperse" with well-defined building blocks and surface functionality, and have garnered significant attention as promising scaffolds for various biomedical applications including drug/gene delivery, targeting, imaging and diagnosis due to their unique physico-chemical properties. [19] [20] [21] [22] [23] [24] [25] These multivalent nanostructures can be tuned conveniently to incorporate various molecules of interest.
Amongst several different types of dendrimers, polyamidoamine (PAMAM) dendrimers have been most widely explored for drug delivery applications due to their commercial availability and aqueous solubility. [26] [27] [28] We previously reported that non-cytotoxic, hydroxyl terminated generation 4 PAMAM dendrimers (PAMAM-G4-OH, 4 nm size) can cross the impaired BBB upon systemic administration and target activated microglia and astrocytes at the site of injury in the brain several folds more than the healthy control in a neonatal brain injury model without any targeting ligand. 29 We further validated these findings in various small and large animal models of neuroinflammtory disorders. [30] [31] [32] [33] [34] [35] [36] [37] The selective uptake and localization of these neutral dendrimers in activated microglia might be attributed to their ability to cross the impaired BBB and diffuse rapidly within the brain parenchyma. 38, 39 Due to their neutral surface, hydroxyl PAMAM dendrimers have a relatively low risk of opsonization upon systemic administration and exhibit low non-specific interactions, which are a major drawback associated with cationic amine functionalized PAMAM dendrimers. [40] [41] [42] Unlike their charged counterparts (PAMAM-NH 2 and PAMAM-COOH), neutral PAMAM-G4-OH dendrimers are nontoxic even at intravenous doses greater than 500 mg/kg. 30, 41 D-NAC is a covalent conjugate of PAMAM-G4-OH attached to Nacetyl cysteine (NAC) through a disulfide linker which can selectively release NAC intracellularly in the presence of glutathione. 30 NAC is a clinically approved anti-inflammatory and anti-oxidative agent but needs to be given at high doses due to its poor bioavailability which can cause neuronal toxicity. 
| M A TER I A LS A N D M ETH OD S

| Synthesis of intermediates and dendrimers
The detailed synthetic procedures are described in the Supporting Information.
| Characterization 2.2.1 | Nuclear magnetic resonance
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 500 MHz spectrometer at ambient temperatures. Proton and carbon chemical shifts (d) are reported in ppm. The resonance multiplicity in the 1 H NMR spectra are described as "s" (singlet), "d" (doublet), "t" (triplet), and "m" (multiplet) and broad resonances are indicated by "b".
Residual protic solvent of to the kit's protocol) was measured using a plate reader at 520 nm with a correction at 550 nm. The NO levels were calculated using the calibration graph equation as per the manufacturer's instructions.
| In vivo targeting of fluorescently labeled Cy5-D-NAC 2.4.1 | Rabbit model of CP and administration of D-NAC-Cy5
Timed-pregnant New Zealand white rabbits were purchased from Robinson Services Inc. (North Carolina) and arrived at the facility one week before surgery. All animals were housed under ambient conditions (228C, 50% relative humidity, and a 12-h light/dark cycle), and necessary precautions were undertaken throughout the study to minimize pain and stress associated with the experimental treatments. Experimental procedures were approved by the Johns Hopkins University Animal Care and Use Committee (IACUC). After one week of acclimation, the pregnant rabbits underwent laparotomy on gestational day 28 (G28) and received a total of 4,800 EU of LPS (E. coli serotype O127:
B8, Sigma-Aldrich, St. Louis, MO) injection along the wall of the uterus as previously described. [49] [50] [51] The kits were induced on G30 with intra- 
| Immunohistochemistry
Kits were anesthetized and transcardially perfused with PBS, followed by 10% formalin. The brains were removed and post-fixed in 10% for- 
| Synthesis of D-NAC and advantages of improved protocol over the previous route
The previous protocol for D-NAC production consisted of four synthetic steps ( Figure 1B) . 32 The first step was the ligation of 4-(fmocamino)butyric acid with PAMAM-G4-OH (1) in the presence of PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate)
as amide coupling reagent to obtain Fmoc-protected bifunctional dendrimer (2), which was followed by the deprotection of Fmoc using piperidine (20% in DMF) to get bifunctional dendrimer (3). The amine termini of dendrimer (3) were then reacted with SPDP (4) to obtain pyridyldithio-functionalized dendrimer (5) as an intermediate which was reacted in situ with NAC to yield D-NAC (6). PAMAM-G4-OH is the most expensive material in the entire synthetic process. The choke point in the previous route was that all the reactions in the protocol were performed on the dendrimer. After each synthetic step on the dendrimer, the product was purified via elaborative dialysis in DMF for 24 h to remove small molecule impurities followed by another 24 h of water dialysis to eliminate DMF. We observed appreciable loss of dendrimer using this purification procedure. Reducing the number of reaction steps on the dendrimer can not only decrease the overall cost but also reduces the synthesis time. Moreover, we realized that since all of the synthesis steps were in sequence on the dendrimer in the previous protocol, it required at least 5-6 days (24 h reaction time, 48 h dialysis time, and 48 h lyophilization) to get the product from one reaction to use it as the reactant in the next step which could be troublesome for its large-scale manufacturing in terms of time and cost.
These issues will be critically evaluated one by one as we discuss the advantages of improved protocol.
To improve the scalability of the protocol, we divided the entire D-NAC synthesis process into two halves. We elected to commence the synthesis in a semi-convergent fashion by the construction of two main intermediates: (a) bifunctional dendrimer (8, Figure 1C PAMAM-G4-OH is received in methanol solution, which is evaporated completely using a rotary evaporator, followed by the dissolution in water and lyophilization. It is very important to remove the traces of methanol and water completely as these interfere in the coupling reaction. We then reacted PAMAM-G4-OH (1, Figure 1C ) with BOC-GABA-OH in the presence of coupling agents [1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP)]
in DMF for 36h at room temperature to yield BOC-protected bifunctional dendrimer (7) . The exact stoichiometry is described in the supporting information. The order of addition of reagents in the reaction should be followed exactly to obtain uniform product distribution with the desired loading of GABA-BOC. The dendrimer, BOC-GABA-OH and DMAP are first dissolved in DMF under Argon atmosphere, followed by the addition of EDC.HCl in portions at the end. The progress of the reaction is monitored by HPLC to ensure the formation of product with the desired loading by comparing it with reference material. Upon completion, the precipitation of the crude product is achieved by adding an excess of hexanes, which is then decanted off.
The precipitates are further washed with ethyl acetate to remove excess reagents and side products. The residue is then diluted with water and dialyzed using a 2 kDa membrane against ultra-pure water for 24 h to further remove trace impurities. We observed that the diluted reaction mixture (30 mL water for 1 g of conjugate) provided the best yield during the dialysis process. In this step, we do not perform any DMF dialysis as all the reagents and side-products are watersoluble, which was not the case in previous protocol using Fmoc-based reagents. The lyophilized product is then characterized by NMR and HPLC as further discussed in the characterization section. The BOCprotected bifunctional dendrimer (7) NAC using this improved protocol with more than 98% purity. We further determined the size of D-NAC to be around 5.8 nm using dynamic light scattering ( Figure 2D , Table 1 ). Zeta potential measurement provided the value around 6.5 mV (Table 1 ).
| Calculation of NAC loading by tris(2-carboxy ethyl) phosphine hydrochloride reduction method
In addition to the NAC loading by proton integration method using 
| Reproducibility of D-NAC synthesis
The most important aim of the improved synthetic protocol is to get a cultures. 52 In this study, we analyzed the results from three different batches of D-NAC synthesized using new route and compared them for reproducibility ( Figure 5A ,B, Table 2 ). The cells were treated with NAC, D-NAC and PAMAM-G4-OH for a brief period of 6 h to ensure maximum uptake 52, 53 and to mimic the in vivo blood circulation of the conjugate. At concentrations of 500 and 1,000 lg/ml, both D-NAC (three batches) and PAMAM-G4-OH did not induce cytotoxicity to the cells. The percent cell viability was greater than 98% for both D-NAC Solubility >200 mg/mL >200 mg/mL >200 mg/mL >200 mg/mL % Cell viability at 1,000 mg/mL >90% >90% >90% >90%
LDH-mediated cytotoxicity at 1,000 mg/mL 10% 9.2% 7% 8.7%
Anti-inflammatory activity (TNF-a suppression at 100 mg/mL compared to free NAC) 2.1 fold 2.5 fold 2.7 fold 2.4 fold Antioxidant activity (NO suppression at 100 mg/mL compared to free NAC) 1.5 fold 1.1% and 8.0 6 0.6%, respectively) ( Figure 5B ). We suspect that this minimal toxicity may be due to the conjugation of NAC on the dendrimer surface since free NAC at treatment concentrations of 100-1,000 lg also showed LDH mediated cytotoxicity of 14.4 6 0.9%, 12.6 6 0.5%, and 10.6 6 0.7%, respectively ( Figure 5B ). Table 2 ). NAC at 1 and 10 lg/mL did not attenuate production of TNF-a, whereas D-NAC demonstrated significant suppression. Interestingly, the TNF-a levels from the cells treated with 1lg/mL D-NAC were similar to that of 100 lg/ mL NAC ( Figure 5C ). There was no significant difference in TNF-a suppression among the three batches at all the treatment concentrations demonstrates reproducible efficacy of D-NAC. This is due to the fact that all the three batches have similar drug loading and purity. Antioxidant activity was evaluated by measuring the nitric oxide (NO) levels released by the cells in to the medium using Griess reagent kit. Activated microglial cells (LPS exposed) showed significant NO release (3.0-fold) compared to non-LPS treated controls ( Figure 5D , Table 2 ).
D-NAC treatment at 10, 100 and 200 lg/mL concentrations significantly decreased NO production. In contrast, only 200 lg/mL dose of NAC was effective in decreasing the level of NO release ( Figure 5D ). 
| 97
This enhanced efficacy can be attributed to enhanced cellular uptake of dendrimers. 47 We have previously demonstrated that the dendrimer uptake is increased when the microglial cells are activated. 55 D-NAC treatment improves intracellular glutathione (GSH) levels while suppressing glutamate release significantly compared to NAC. 3.9 | Another synthetic approach for conjugation of NAC on dendrimer surface
While we were redesigning the synthesis of D-NAC, we also developed another synthetic route which can yield dendrimer-NAC conjugate. In this route, we generated ether bound linker on the dendrimer surface.
The ether linkages are robust, do not undergo hydrolysis and are not substrates of esterase. For this purpose, we reacted PAMAM-G4-OH
(1) with allyl bromide in the presence of sodium hydride to conjugate 22-24 allyl arms on the dendrimer surface by ether bonds (11, Figure   7A ). The alkene groups on dendrimer surface were then reacted with BOC-aminoethane thiol under UV light (365 nm) using highly efficient and orthogonal photocatalyzed thiol-ene click reaction to afford BOC protected dendrimer 12. Thiol-ene click is a highly robust and scalable reaction; and has been tremendously used to fabricate several 
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